The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).

RemeGen Co., Ltd. has disclosed the current composition of its board of directors, which includes five executive directors, one non-executive director, and three independent non-executive directors, with Wang Weidong serving as chairman. The company also detailed the membership and chairperson roles across its four key board committees—Audit, Remuneration and Appraisal, Nomination, and Strategy—clarifying governance responsibilities and reinforcing its corporate oversight structure.

The announcement underscores RemeGen’s emphasis on formal governance and committee-based oversight, which is important for investors tracking board independence and accountability in a regulated biopharmaceutical market. By clearly allocating leadership roles and committee memberships, the company signals a structured decision-making framework that may support regulatory compliance, risk management, and strategic execution for stakeholders.

The most recent analyst rating on (HK:9995) stock is a Buy
with a HK$129.00 price target.
To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock,
see the HK:9995 Stock Forecast page.